WHO Expert Committee on Selection and Use of Essential Medicines

E902881

WHO expert committee advisory body health policy advisory committee

The WHO Expert Committee on Selection and Use of Essential Medicines is a specialized World Health Organization body that evaluates evidence and advises which medicines should be prioritized globally for inclusion on the Model List of Essential Medicines.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (3)

Label	Occurrences
WHO Expert Committee on Selection and Use of Essential Medicines canonical	1
World Health Organization expert committees	1
https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines	1

How this entity was disambiguated

This entity first appeared as the object of triple T11074389 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: WHO Expert Committee on Selection and Use of Essential Medicines
Context triple: [World Health Organization Model List of Essential Medicines, governedBy, WHO Expert Committee on Selection and Use of Essential Medicines]

A. World Health Organization Model List of Essential Medicines
The World Health Organization Model List of Essential Medicines is a periodically updated catalog of the most effective, safe, and cost-efficient medicines deemed essential for meeting the priority health needs of populations worldwide.
B. WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
C. Doha Declaration on the TRIPS Agreement and Public Health
The Doha Declaration on the TRIPS Agreement and Public Health is a 2001 WTO ministerial statement affirming that intellectual property rules should not prevent members from protecting public health and ensuring access to affordable medicines.
D. World Health Organization Council on the Economics of Health for All
The World Health Organization Council on the Economics of Health for All is a high-level advisory body that rethinks and promotes economic policies to prioritize health as a global public good and central goal of development.
E. Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: WHO Expert Committee on Selection and Use of Essential Medicines
Target entity description: The WHO Expert Committee on Selection and Use of Essential Medicines is a specialized World Health Organization body that evaluates evidence and advises which medicines should be prioritized globally for inclusion on the Model List of Essential Medicines.

A. World Health Organization Model List of Essential Medicines
The World Health Organization Model List of Essential Medicines is a periodically updated catalog of the most effective, safe, and cost-efficient medicines deemed essential for meeting the priority health needs of populations worldwide.
B. WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
C. Doha Declaration on the TRIPS Agreement and Public Health
The Doha Declaration on the TRIPS Agreement and Public Health is a 2001 WTO ministerial statement affirming that intellectual property rules should not prevent members from protecting public health and ensuring access to affordable medicines.
D. World Health Organization Council on the Economics of Health for All
The World Health Organization Council on the Economics of Health for All is a high-level advisory body that rethinks and promotes economic policies to prioritize health as a global public good and central goal of development.
E. Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
F. None of above. chosen

Statements (49)

Predicate	Object
instanceOf	WHO expert committee ⓘ advisory body ⓘ health policy advisory committee ⓘ
advises	World Health Organization ⓘ
advisesOn	criteria for inclusion and deletion of medicines from the Model List of Essential Medicines ⓘ selection of essential medicines ⓘ updating the WHO Model List of Essential Medicines ⓘ use of essential medicines ⓘ
aimsTo	improve access to essential medicines ⓘ promote rational use of medicines ⓘ support universal health coverage ⓘ
appliesCriterion	comparative cost-effectiveness ⓘ evidence on efficacy ⓘ evidence on safety ⓘ feasibility of use in different health system settings ⓘ public health relevance ⓘ
composedOf	independent experts in clinical medicine ⓘ independent experts in health economics ⓘ independent experts in pharmacology ⓘ independent experts in public health ⓘ
convenes	at WHO headquarters in Geneva ⓘ
fieldOfWork	essential medicines ⓘ evidence-based medicine ⓘ global health ⓘ medicines selection ⓘ pharmaceutical policy ⓘ rational use of medicines ⓘ
hasMainResponsibility	evaluating applications for inclusion of medicines on the Model List of Essential Medicines ⓘ issuing recommendations on which medicines should be considered essential at global level ⓘ providing guidance to countries on national essential medicines lists ⓘ reviewing evidence on efficacy, safety and cost-effectiveness of medicines ⓘ updating the WHO Model List of Essential Medicines ⓘ updating the WHO Model List of Essential Medicines for Children ⓘ
influences	global pharmaceutical policy ⓘ national essential medicines lists ⓘ
language	English ⓘ
meets	periodically ⓘ
operatesUnder	WHO Department of Essential Medicines and Health Products ⓘ
parentOrganization	World Health Organization ⓘ
partOf	World Health Organization ⓘ
produces	WHO Technical Report Series publications ⓘ reports of the Expert Committee on the Selection and Use of Essential Medicines ⓘ
scope	global ⓘ
usesMethod	assessment of comparative efficacy ⓘ assessment of cost-effectiveness ⓘ assessment of safety ⓘ public consultation on applications ⓘ systematic review of clinical evidence ⓘ
website	https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines ⓘ linked to: WHO Expert Committee on Selection and Use of Essential Medicines

How these facts were elicited

Referenced by (3)

Full triples — surface form annotated when it differs from this entity's canonical label.

World Health Organization Model List of Essential Medicines → governedBy → WHO Expert Committee on Selection and Use of Essential Medicines ⓘ

İhsan Doğramacı → memberOf → World Health Organization expert committees ⓘ

linked to: WHO Expert Committee on Selection and Use of Essential Medicines

WHO Expert Committee on Selection and Use of Essential Medicines → website → https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines ⓘ